The use of bedaquiline in regimens to treat drug-resistant and drug-susceptible tuberculosis: a perspective from tuberculosis-affected communities

by Laia Ruiz Mingote, Dorothy Namutamba, Francis Apina et al.
The Lancet, Early Online Publication, 11 July 2014

3 pp. 58 kB:
http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673614605237.pdfS0140673614X60927_cov150h

As the first new drug from a novel class approved to treat tuberculosis in more than 40 years, bedaquiline’s implications for improving treatment of drug-resistant tuberculosis and possible application to create shorter first-line regimens for treatment of drug-susceptible tuberculosis is still unclear. Community voices on bedaquiline’s use to treat drug-resistant tuberculosis and future development as a potential treatment for drug-susceptible disease have been largely unheard. The authors provide a community perspective on this issue and list seven questions concerning bedaquiline’s safety that researchers should answer before the launch of clinical trials of bedaquiline for drug-susceptible tuberculosis.

(Visited 30 times, 1 visits today)
This entry was posted in Essential Medicines, General, Tuberculosis. Bookmark the permalink.